All Type of News
AstraZeneca’s Crestor to be exposed to cutthroat competition
AstraZeneca (AZ)’s Crestor (rosuvastatin) will not be as stable as before with a growing number of pharmaceutical companies poising to enter a 50 billion Crestor market.
A total of 60 pharmaceutical manufacturers ...
KPMA seeks to integrate anti-rebate provisions
The Korea Pharmaceutical Manufacturers Association is considering incorporating the two different fair trade provisions and self-regulatory pact by the manufacturers to ban the provision of rebates, which have been pr...
State to cover cost-effective drugs
The Health Insurance Review Agency said it has evaluated the effectiveness of existing medicines in order to decide whether they are eligible for the insurance list.
The number of medicines to be screened within t...
Report on glucosamine supplement stirs heated debate
A new report showed that the highly praised dietary supplement, glucosamine, or glucosamine sulfate, is useless in treatment of mild to moderate osteoarthritis.
The report, which was released on February 2 by the N...
Yooyoung signs marketing agreement for novel combination of pravastatin and fenofibrate
Yooyoung Pharm says it has recently entered into an exclusive agreement with Belgium based 'LABORATOIRES SMB S.A. to locally market Pravafen, a combination of fenofibrate and pravastatin to treat mixed dyslipidemia.
...
Local drugmakers urged to join W1 trillion club in sales
Many say Korean pharmaceutical companies should go all-out to reach “1-trillion-won club'' in sales in the near future.
The potential drug maker to achieve this record is Dong-A Pharm, which exceeded 800 billion in...
KFDA simplifies vendor audit procedures
Drug makers will share the contents of a vendor audit if they purchase raw material from the same supplier, the Korea Food and Drug Administration said.
Under the current cGMP (current Good Manufacturing Practice) ...
Yuhan to market Zirtec
Yuhan Corporation said the company will market UCB’s popular antihistamine drug Zirtec (cetirizine) for the next five years here as it took over its marketing right from Samil Pharm.
Yuhan will step up their market...
KFDA reviews generic raw materials of Joins
The Korea Food and Drug Administration has begun to review raw materials and manufacturing process of Joins generics in four manufacturing sites from last week, a source said recently. Joins is an arthritis drug devel...
Medical bill for lung cancer patients goes down
Korea’s National Health Insurance has expanded its coverage to Eli Lilly’s chemotherapy drug Alimta (pemetrexed) as the first line drug for locally advanced or metastatic, nonsquamous, non-small cell lung cancer, acco...
